orforglipron and retatrutide Orforglipron: Phase 3 Data Shows Ozempic-Like Results, In Pill Form The NEW Ozempic Replacements: Retatrutide,

Ongoing clinician oversight Provider-guided dosing and check-ins throughout your plan

those with a lower BMR will have more difficulty burning calories, which makes losing weight more challenging

While compounded formulations are not FDA-approved as finished products, they use FDA-approved active pharmaceutical ingredients and follow established pharmaceutical compounding practices

Drinking more water fills you up more

More realistic scenario: FDA approval 2028, commercial launch Q3-Q4 2028, shortages through early 2029, stable availability mid-2029

Ethics declarations Conflict of Interest The authors declare that they have no conflicts of interest